Sanofi revealed a setback alongside news of another blow to venglustat.
Sanofi is narrowing development of one of its 5 billion euro ($5.4 billion), “pipeline-in-a-product” assets. The French drugmaker axed Sjögren’s syndrome from the list of targeted indications for frexalimab after seeing phase 2 efficacy data—and reported a phase 3 flop for one of its tarnished former top prospects.
The company began comparing frexalimab, also known as SAR441344, to placebo in Sjögren’s in 2020. The goal was to show whether the candidate can improve scores on a Sjögren’s disease activity scale. Sanofi revealed the molecule fell short as part of its first-quarter results (PDF) Thursday.
“The data confirmed pharmacologic activity and well-tolerated safety profile but not the necessary efficacy outcomes to continue to move forward the development in this indication,” Sanofi said. The findings of the 84-patient phase 2 trial persuaded Sanofi to stop development in Sjögren’s. Development in other, potentially more lucrative indications is continuing.
Sanofi revealed the setback alongside news of another blow to venglustat, a GCS inhibitor that has slipped down the pecking order in recent years. Venglustat was among the assets that Paul Hudson identified as Sanofi's top prospects when he took over as CEO in 2019. However, the drugmaker stopped a phase 2/3 trial in autosomal dominant polycystic kidney disease in 2021.
Sanofi said the phase 3 GM2 trial “reinforced the favorable safety profile” of venglustat. Development is continuing in Fabry and Gaucher, settings in which Sanofi could file for approval in 2025 and beyond.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.